Sign inJoin waitlistJoin the waitlist

Andrew Evens

Deputy Director Clinical Services and Chief Physician Officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center · Rutgers Health

Credentials: · · · · · · · · ·

History

Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center · Rutgers Health
Present
Rutgers Health
Present

Northwestern University
1999–2002
Internal Medicine
1996–1999
Chicago College of Osteopathic Medicine
1992–1996

Research

Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma
Cell · 2017 · 918 citations
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
Blood · 2009 · 694 citations
The genetic landscape of mutations in Burkitt lymphoma
Nature Genetics · 2012 · 470 citations

Leo Gordon
61 papers
Jane Winter
36 papers
Sonali Smith
28 papers
Susan Parsons
26 papers
MT
Martin Tallman
24 papers
BK
Brad Kahl
22 papers
Jonathan Friedberg
22 papers
Reem Karmali
21 papers
KD
Kevin David
20 papers · 2 as a fellow
Jayesh Mehta
18 papers
Julie Vose
18 papers
Nancy Bartlett
18 papers

Grants

Modeling Multi-Source Data in Hodgkin Lymphoma
National Cancer Institute · R01
PI · $3.6M · Tufts Medical Center
2022–2027
Determining Treatment Sensitivity in B Cell Lymphoma by Novel Microfluidics-Based NK Cell Immunogenicity Platform
National Cancer Institute · R33
PI · $1.2M · Northeastern University
2018–2022
MAP Kinase Signaling in Lymphoma: A Novel Therapeutic Paradigm
National Cancer Institute · R01
Contact PI · $1.4M · Tufts Medical Center
2012–2017
Research Training in Oncology
National Cancer Institute · T32
Contact PI · $253.2K · Tufts Medical Center
1981–2015

Clinical trials

Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Principal investigator · Terminated · Phase 2
Spectrum Pharmaceuticals, Inc
2011–2015
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
Principal investigator · Completed · Phase 2
ECOG-ACRIN Cancer Research Group
2011–2019
Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL
Principal investigator · Completed · Phase 2
Northwestern University
2006–2014
Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Principal investigator · Completed · Phase 1, Phase 2
Pharmacyclics LLC.
2005–2007